Welcome to our dedicated page for Calumet SEC filings (Ticker: CLMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Calumet, Inc. (NASDAQ: CLMT), a petroleum refineries industry company that manufactures, formulates and markets specialty branded products and renewable fuels. Through these filings, investors can review Calumet’s regulatory disclosures on operations, financing activities, internal controls and segment performance across Specialty Products and Solutions, Montana/Renewables, Performance Brands and Corporate.
Current reports on Form 8-K are a central source of Calumet information. The company uses Item 2.02 filings to furnish results of operations and financial condition for specific quarters, referencing press releases that contain detailed financial data. These 8-Ks allow readers to see how Calumet reports quarterly performance, including metrics such as net income (loss) and non-GAAP measures like Adjusted EBITDA and Adjusted EBITDA with Tax Attributes, which the company explains in its disclosures.
Calumet has also filed 8-Ks under Item 4.02 describing non-reliance on previously issued financial statements. In one such filing, the Audit Committee concluded that unaudited interim consolidated financial statements for certain 2025 periods required restatement due to an error in the unaudited condensed consolidated statements of cash flows. The company explained that the error involved misclassification between operating and financing cash flows, did not affect revenue, net income (loss) or cash and cash equivalents, and was associated with a material weakness in internal control over financial reporting. The filing outlines planned restatements and discussions with the independent registered public accounting firm.
Other 8-K filings detail material definitive agreements and related transactions. For example, Calumet reported a sale and leaseback transaction for property comprising the Shreveport refinery fuels terminal, truck rack and related piping and equipment, documented under a Master Lease Agreement and property schedule with Stonebriar Commercial Finance LLC. The filing describes lease terms, rental payments, an option to repurchase the leased assets, application of proceeds to prior obligations, and related amendments to the company’s credit agreement and monetization master agreement.
Calumet’s filings also reference its capital structure, including various series of senior notes such as 11.00% Senior Notes due 2026, 8.125% Senior Notes due 2027, 9.75% Senior Notes due 2028 (including a mirror issuance), and 9.25% Senior Secured First Lien Notes due 2029. Definitions of "Consolidated Cash Flow" and "Consolidated EBITDA" used in these instruments are linked to the company’s non-GAAP measures, and the filings explain how these metrics are reported to noteholders and lenders.
On Stock Titan, Calumet’s SEC filings are updated from EDGAR and presented with AI-powered summaries. AI analysis highlights key terms in 10-K and 10-Q reports, explains complex sections such as non-GAAP reconciliations and covenant definitions, and surfaces important items from 8-Ks, including restatement notices, internal control disclosures and material transactions. Users can also review Form 4 and other ownership filings to track insider transactions, alongside proxy and other statements that address governance and compensation when available.
By combining real-time access to Calumet’s SEC submissions with AI-generated explanations, this page helps readers understand how the company reports its specialty products and renewable fuels operations, manages its capital structure and addresses financial reporting and control matters in its official filings.
Jennifer Straumins, a director of Calumet, Inc. (CLMT), received 3,796 Restricted Stock Units on 06/24/2025. The RSUs are fully vested and each unit is the economic equivalent of one share of common stock; they may be settled in one share each or in cash for the cash value. The transaction was coded M and reported as having a $0 price. After the grant, Ms. Straumins is reported to beneficially own 938,385 shares of Calumet common stock. The Form 4 was signed by an attorney-in-fact on 10/03/2025. This filing documents an insider compensation-related grant and confirms the director's current beneficial ownership level.
Daniel J. Sajkowski, a director of Calumet, Inc. (CLMT), reported transactions dated 06/24/2025. He received 3,796 Restricted Stock Units (RSUs) that are 100% vested and economically equivalent to one share each; these RSUs were reported as to be settled in the cash equivalent of common stock. On the same date he reported a disposition of 1,518 shares. After these transactions he beneficially owns 164,237 shares of Calumet common stock. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The filing notes the RSUs may be settled in shares or cash and that the reporter elected to receive 40% of vested RSUs in cash equivalent.
Calumet, Inc. (CLMT) director John G. Boss reported two transactions on 06/24/2025. He received 3,796 Restricted Stock Units that are fully vested and economically equivalent to one share each; the filing shows these RSUs were reported as acquired and may be settled in stock or cash. Separately, he disposed of 1,518 shares in a sale reported the same day. After these transactions the filing shows 27,278 shares beneficially owned following the sale and 28,796 held following the RSU acquisition (table ordering reflects both entries).
The form is filed individually and signed by an attorney-in-fact. The filing clarifies that each RSU equals one common share and that the reporting person elected to receive 40% of vested RSUs in cash equivalent form.
Stephen P. Mawer, a director of Calumet, Inc. (CLMT), reported transactions dated 06/24/2025 on Form 4. He was credited with 7,403 Restricted Stock Units (reported as an acquisition) that are 100% vested and each equals one share or the cash value of one share. He separately reported a sale of 2,962 common shares on the same date. The filings show beneficial ownership rising to 291,055 shares after the RSU acquisition and ending at 288,093 shares following the sale. The reporting person elected to receive 40% of vested RSUs in the cash equivalent of common shares.
Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi report beneficial ownership of 4,497,609 shares of Calumet, Inc. common stock, representing 5.2% of the 86,659,413 shares outstanding referenced for the period ended June 30, 2025. These shares are held by Two Seas Global (Master) Fund LP (the Global Fund).
The filing states that Two Seas Capital (TSC) has sole voting and sole dispositive power over the 4,497,609 shares through its role as investment adviser, that Two Seas Capital GP LLC serves as general partner of TSC, and that Sina Toussi serves as managing member of TSC GP and chief investment officer of TSC. The reporting persons certify the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.
Calumet, Inc. (CLMT) reported a sharply weaker first half of 2025. Sales were $2,020.5 million for the six months versus $2,139.5 million a year earlier, producing a gross loss of $125.0 million compared with a $142.3 million gross profit last year. Operating results swung to a $149.7 million operating loss for six months and a $309.9 million net loss (versus $80.7 million net loss a year earlier). For the quarter, sales were $1,026.6 million and net loss was $147.9 million, or $1.70 per share on 86.8 million weighted average shares.
Balance sheet and cash flow highlights show total assets of $2,776.4 million and total liabilities of $3,540.5 million, leaving stockholders' equity at a $1,009.7 million deficit. Cash and restricted cash totaled $190.6 million at June 30, 2025. The Company recorded a $457.0 million RINs obligation (current) and had net cash used in operating activities of $108.0 million for the six months. Material transactions included a March 31, 2025 closing of the sale of the industrial portion of Royal Purple for $110.0 million (net proceeds received $95.4 million) producing a $62.2 million gain, and a DOE Loan Guarantee for MRL totaling $1.44 billion with a first tranche disbursement of $781.8 million.
Calumet, Inc. filed a current report describing that it has released its financial results for the quarter ended June 30, 2025. On August 8, 2025, the company issued a press release with its results of operations and financial condition, which is furnished as Exhibit 99.1 to this report rather than being treated as formally filed. The report also notes inclusion of Exhibit 104, which contains the cover page interactive data file with XBRL tags embedded in the Inline XBRL document.
Calumet, Inc. (CLMT) Form 4 – director equity award
Director Paul C. Raymond disclosed two Restricted Stock Unit (RSU) grants dated 08-05-2025:
- 1,611 fully-vested RSUs that will settle on the earlier of a date selected by the director or his termination from service.
- 537 RSUs issued under the Deferred Compensation Plan; 25 % vest each July 1 beginning 07-01-2026 and settle on the same earlier-of dates.
Both grants were acquired at $0; no shares were sold. Raymond’s directly held derivative equity rises to 2,148 RSUs. The transaction reflects standard board compensation and modestly increases insider alignment, but it does not involve open-market buying or selling that would materially affect share supply or trading sentiment.
Calumet, Inc. (CLMT) – Form 4 insider filing
Director John G. Boss reported the acquisition of 644 restricted stock units (RSUs) on 05 Aug 2025. The filing lists two grants: 483 fully-vested RSUs that will settle on the earlier of a specified date or the director’s termination, and 161 RSUs issued under the company’s Deferred Compensation Plan, vesting 25 % annually beginning 01 Jul 2026. Each RSU converts 1-for-1 into common stock at $0 cost and is held directly by the director.
No shares were sold or transferred, so Mr. Boss’ beneficial ownership in Calumet increased by the same amount. The award appears to be routine director compensation and does not involve open-market transactions.
Calumet, Inc. (CLMT) Form 4 reports that director Stephen P. Mawer was granted a total of 2,954 restricted stock units (RSUs) on 08/05/2025 at an exercise price of $0.
The award is split into (i) 2,216 fully-vested RSUs that will settle upon the earlier of a date selected by the director or his termination, and (ii) 738 RSUs issued through the company’s Deferred Compensation Plan that vest 25 % each July 1 beginning 07/01/2026. Each RSU is economically equivalent to one share of Calumet common stock.
After the grant, Mawer directly holds 2,954 derivative securities convertible into common shares; no open-market purchases or sales were disclosed. The filing reflects routine equity compensation, strengthens management-shareholder alignment, and introduces only minor prospective dilution with no immediate impact on earnings or cash flow.